gsk-249320
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00622609)
Timeline
Indications
Studied for
Mechanism of action
- Myelin-associated glycoproteinINHIBITOR
MAG inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109573 ↗
Also known as
- gsk249320
- gsk249320
- gsk-249320
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01808261 | Phase 2 | May 1, 2013 | GlaxoSmithKline |
| NCT00833989 | Phase 2 | Jul 1, 2009 | GlaxoSmithKline |
| NCT00622609 | Phase 1 | Aug 1, 2007 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2007 |
1 organizations
Page 1 / 1